Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Clinical-stage cancer biotech Nouscom raises $135M in Series D funding to advance its lead cancer vaccine through Phase 2 trials.
Amount Raised
$135 Million
Round Type
Series D
BaselBiotechnologyHealth CareTherapeuticsDescription
Nouscom, a clinical-stage cancer biotechnology company, has raised $135 million in an oversubscribed Series D funding round. The capital will be used to advance the company's lead cancer vaccine candidate through Phase 2 clinical trials. This funding demonstrates investor confidence in Nouscom's therapeutic approach to treating cancer.
Fundz sees it the moment Nouscom raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nouscom raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.